Frédéric Joël Desdouits
Chief Executive Officer chez TreeFrog Therapeutics SAS
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Kevin Alessandri | M | - |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | - |
Julien Dodet | M | - |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Eric Ducournau | M | 56 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 11 ans |
Julia Berretta | M | 43 |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | - |
Jean-Luc René Treillou | M | - |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | - |
Maxime Feyeux | M | - |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | - |
Michael Frédéric Danon | M | - |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 11 ans |
Jean-Francois Le Bigot | M | - |
Citoxlab France SAS
Citoxlab France SAS Miscellaneous Commercial ServicesCommercial Services Citoxlab France SAS operates as a research laboratory. It offers services in toxicology, genomics, pharmacology, pharmacokinetics, bio-analysis, ecotoxicology, stability testing and regulatory affairs. The company was founded in 1969 and is headquartered in Miserey, France. | - |
Peter Zippelius | M | 45 |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | 3 ans |
Marie-France Marchand-Baylet | F | - |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 7 ans |
Olivier Lesueur | M | - |
Bionest Partners SAS
Bionest Partners SAS Miscellaneous Commercial ServicesCommercial Services Bionest Partners SAS operates as a global consulting firm which focuses on pharma, biotech, medical device and diagnostics. It offers strategy development, product planning and assessment services. The company was founded by Robert J. Easton and Alain J. Gilbert and is headquartered in Paris, France. | 20 ans |
Thierry Laugel | M | 57 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Fabrice Chouraqui | M | - |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Guillaume Dureau | M | 62 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Loan Hoang-Sayag | M | 57 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Laurent Higueret | M | - |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | 3 ans |
Philippe Knoche | M | 55 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Jean-Michel Petit | M | - |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | - |
Corinne Spilios | F | 54 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Vincent Touraille | M | 61 | - | |
Suet-Fern Lee | F | 66 | 9 ans | |
Alexander Scheer | M | 61 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 4 ans |
Matthew P. Pando | M | 52 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 ans |
Luc Etienne Péligry | M | 59 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 6 ans |
Loïc Maurel | M | 69 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 ans |
Carole Piwnica | F | 66 | 12 ans | |
Jean Zetlaoui | M | - | 19 ans | |
Philippe Rousseau | M | 53 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 6 ans |
Nitza Thomasson-Perret | M | 51 | - | |
Stefan Oelrich | M | 55 | 7 ans | |
Maud Brandely | M | 70 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | - |
Thierry Denjean | M | - |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | - |
Pierre Schreiner | M | - | - | |
Essy Mozaffari | M | - | - | |
Matthew Ros | M | 57 | 2 ans | |
Wayne Pisano | M | 69 | - | |
Jez Moulding | M | - | - | |
Hervé Duchesne de Lamotte | M | 68 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 3 ans |
Thomas DesRosier | M | 69 | 2 ans | |
Didier Miraton | M | 65 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | - |
Jean-Sébastien Cleiftie | M | 50 | 6 ans | |
Elias Zerhouni | M | 72 | 7 ans | |
Isabelle Barber | M | 55 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
France | 43 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Frédéric Joël Desdouits
- Réseau Personnel